Method for separating dapagliflozin and alpha-isomer thereof

A separation method and isomer technology, applied in the separation of dapagliflozin and its α-isomers, in the field of dapagliflozin, can solve the problems of chiral isomer impurities affecting the quality of drugs, etc., and achieve the analytical method Stable and reliable, high feasibility and strong practicability

Active Publication Date: 2016-04-13
上海柏狮生物科技有限公司
View PDF2 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0013] Aiming at the above-mentioned technical problems in the prior art, the present invention provides a method for separating Dapagliflozin and its α-isomer. The sep...

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Method for separating dapagliflozin and alpha-isomer thereof
  • Method for separating dapagliflozin and alpha-isomer thereof
  • Method for separating dapagliflozin and alpha-isomer thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0036] A method for separating dapagliflozin and its α-isomer, the steps are as follows:

[0037] Take 7.0mg of Dapagliflozin and its α-isomer respectively, put them in a 20mL volumetric flask, add acetonitrile-water to dissolve and dilute to the volume, shake well, and use it as the test solution; Chromatographic apparatus, PhenomenexLunaC (18) (250 × 4.6mm, 5μm) with octadecyl bonded silica gel as filler as chromatographic column, with a mixture of acetonitrile and water as mobile phase, using the following chromatographic separation conditions Separation:

[0038] The mobile phase flow rate is 1.0mL / min;

[0039] The temperature of the chromatographic column is 25°C;

[0040] The injection volume is 10 μL;

[0041] The detection wavelength is 210nm;

[0042] In the mobile phase, calculated by volume percentage, acetonitrile: water is 37%: 63%.

[0043] Chromatographic separation results see figure 1 shown, from figure 1 It can be seen from the figure that Dapaglifloz...

Embodiment 2

[0045] A method for separating dapagliflozin and its α-isomer, the steps are as follows:

[0046]Take 10.0mg of Dapagliflozin and its α-isomer respectively, put them in a 20mL volumetric flask, add acetonitrile-water to dissolve and dilute to the volume, shake well, and use it as the test solution; Chromatographic apparatus, PhenomenexLunaC (18) (250 × 4.6mm, 5μm) with octadecyl bonded silica gel as filler as chromatographic column, with a mixture of acetonitrile and water as mobile phase, using the following chromatographic separation conditions Separation:

[0047] The mobile phase flow rate is 1.0mL / min;

[0048] The temperature of the chromatographic column is 25°C;

[0049] The injection volume is 10 μL;

[0050] The detection wavelength is 210nm;

[0051] In the mobile phase, calculated by volume percentage, acetonitrile: water is 32%: 68%.

[0052] Chromatographic separation results see figure 2 shown, from figure 2 It can be seen from the figure that Dapaglifl...

Embodiment 3

[0054] A method for separating dapagliflozin and its α-isomer, the steps are as follows:

[0055] Take 10.0mg of Dapagliflozin and its α-isomer respectively, put them in a 20mL volumetric flask, add acetonitrile-water to dissolve and dilute to the volume, shake well, and use it as the test solution; Chromatographic apparatus, PhenomenexLunaC (18) (250 × 4.6mm, 5μm) with octadecyl bonded silica gel as filler as chromatographic column, with a mixture of acetonitrile and water as mobile phase, using the following chromatographic separation conditions Separation:

[0056] The mobile phase flow rate is 1.0mL / min;

[0057] The temperature of the chromatographic column is 25°C;

[0058] The injection volume is 10 μL;

[0059] The detection wavelength is 210nm;

[0060] In the mobile phase, calculated by volume percentage, acetonitrile: water is 42%: 58%.

[0061] Chromatographic separation results see image 3 shown, from image 3 It can be seen from the figure that Dapagliflo...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Wavelengthaaaaaaaaaa
Wavelengthaaaaaaaaaa
Login to view more

Abstract

The invention belongs to the technical field of pharmaceutical analysis, and provides a method for separating dapagliflozin and an alpha-isomer thereof. A high performance liquid chromatographic analyzer is adopted, a chromatographic column with octadecyl bonded silica as a filler is adopted, and the specification is 4.6mm*250mm, 5[mu]m; the mobile phase is an acetonitrile and water mixed liquid or a methanol and water mixed liquid, a volume ratio of acetonitrile to water is 32-42:58-68, and a volume ratio of methanol to water is 60-80:20-40; the flow velocity is 0.6-1.2mL/min; the column temperature is 20-40DEG C; the wavelength of an ultraviolet detector is 205-260nm; and the sample introduction volume is 10[mu]m, a compound having the after coming peak is the alpha-isomer, and a compound having the first-out peak is dapagliflozin. The method has the advantages of just use of a common liquid chromatograph, low device requirements, common and easily available media selected as the mobile phase, high feasibility, and simple and convenient operation process.

Description

technical field [0001] The invention belongs to the field of medicinal chemistry, and relates to a dapagliflozin, in particular to a method for separating dapagliflozin and its α-isomer. Background technique [0002] The chemical name of Dapagliflozin is (2S,3R,4R,5S,6R)-2-[3-(ethoxyphenyl)-4-chlorophenyl]-6-hydroxymethyltetrahydro- 2H-pyran-3,4,5-triol. The SGLT2 inhibitor jointly developed by AstraZeneca and Bristol-Myers Squibb was approved by EMA and FDA on November 14, 2012 and January 8, 2014 respectively, becoming the successor to Canaglifloz The second FDA-approved SGLT2 inhibitor after the net. The drug selectively inhibits SGLT2 in the kidneys and removes excess sugar and calories in the urine, helping to lower blood sugar levels. It can be used as an important choice in diabetes drug treatment, and the structural formula of Dapagliflozin is shown below. [0003] [0004] The chemical structure of dapagliflozin [0005] According to the literature reports o...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): G01N30/02G01N30/06
CPCG01N30/02G01N30/06G01N2030/027
Inventor 潘仙华王亚萍李勤勤张瑞敏陈思羽张鑫陈彦宇
Owner 上海柏狮生物科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap